Drug Type Aptamers |
Synonyms |
Target |
Mechanism CCL2 inhibitors(C-C motif chemokine 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Preclinical | CZ | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Preclinical | PL | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Preclinical | HU | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Preclinical | RO | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Preclinical | DE | 01 Mar 2012 | |
Diabetic Nephropathies | Preclinical | RO | - | |
Diabetic Nephropathies | Preclinical | HU | - | |
Diabetic Nephropathies | Preclinical | PL | - | |
Diabetic Nephropathies | Preclinical | DE | - | |
Diabetic Nephropathies | Preclinical | CZ | - |
Phase 1 | Diabetic Nephropathies CCL2 (MCP-1) | - | kunigxpzrw(fudnjrgplv) = tqsmlpjjin yemayiscfx (glqqmgabyh ) View more | Positive | 30 Oct 2012 | ||
Placebo | kunigxpzrw(fudnjrgplv) = pcijaisagd yemayiscfx (glqqmgabyh ) |